Considering the growing list of synthetic lethal gene pairs with ARID1A deficiency, it may be interesting to investigate the efficacy of combinational therapy of PLK1 inhibitor and agents targeting synthetic lethal phenotypes in ARID1A-mutated cancers, such as PARP inhibitors and ATR inhibitors. This evidence concerns the gene PLK1 and cancer.